Stockwinners Market Radar for July 25, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:05 EDT Cathie Wood's ARK Investment bought 252K shares of Iridium today

19:56 EDT Oracle wins copyright case against Rimini Street - The company states: "Yesterday, the United States District Court for the District of Nevada ruled that Rimini Street repeatedly and illegally infringed Oracle's copyrights, impermissibly removed Oracle's copyright notices from Oracle software, and made at least 15 types of false statements regarding its support practices. As a result, the Court entered another permanent injunction requiring Rimini to immediately and permanently discontinue use of various support programs while further limiting others. The Court also found Rimini's founder and CEO, Seth Ravin, personally liable for Rimini's copyright infringement, copyright notice removal, and false advertising, ruling that Mr. Ravin "knowingly participated in the creation and propagation of Rimini's false advertising." As part of its injunction, the Court is requiring Rimini to issue a corrective press release to make its customers and prospective customers aware of the "false and misleading statements that Rimini Street has made in its advertisements and marketing campaigns."

19:24 EDT Monolithic Power CEO sells $15.4M in common stock - In a regulatory filing, Monolithic Power disclosed that its CEO Michael Hsing sold 28.8K shares of common stock on July 21st in a total transaction size of $15.4M.

18:33 EDT NexPoint Real Estate announces regular and special dividends - NexPoint Real Estate Finance announced that its board of directors has declared a quarterly regular dividend of 50 per share of NREF common stock. The Company also announced that its board of directors has declared a special dividend of 18.5c per share of NREF common stock. The regular and special dividends will be payable on September 29 to stockholders of record on September 15.

17:42 EDT Snap says providing formal guidance again 'a big shift' for company - Says providing formal guidance again 'a big shift' for the company. Says tries to reasonably include attainable upside to business when giving guidance. Comments taken from Q2 earnings conference call.

17:22 EDT Robert Half extends after-hours decline to 13% after below-consensus guidance

17:06 EDT INNOVATE Corp. names Paul Voigt as interim CEO - INNOVATE "announced that the Board has named Paul K. Voigt Interim Chief Executive Officer, effective immediately. Suzi Herbst, who had been serving as interim CEO immediately following the passing of Wayne Barr, will remain the Company's Chief Operating Officer. Voigt joins INNOVATE from Lancer Capital, where he served as Senior Managing Director of Investments. He previously served as Senior Managing Director of Investments at INNOVATE from 2014 to 2018."

17:00 EDT PacWest Bancorp trading resumes

16:50 EDT Ra Capital discloses $40M purchase of Acumen common stock - RA Capital increases its stake in Acumen by 5.2M shares to 14.9M shares from 5.2M with a stock purchase of $40M. Shares of Acumen are up 4.4% afterhours at $7.21.

16:46 EDT Amarin gets positive pricing news from Spain regulator for Vazkepa to treat CVD - Amarin announces that following the most recent meeting of the Spanish Drug Pricing Committee on July 24, the Committee is recommending the national reimbursement of VAZKEPA or icosapent ethyl, to reduce the risk of cardiovascular events in patients with high cardiovascular risk . "Cardiovascular disease is still one of Spain's leading causes of death and patients with this disease need access to new treatments that can reduce their risk of having another event. I am very pleased to see that our health authorities are now making icosapent ethyl available in Spain which has shown to significantly reduce cardiovascular risk and help to prevent future heart attacks or strokes in these high cardiovascular risk patients," said Professor Luis Rodriguez Padial, cardiologist, and elected president of the Spanish Society of Cardiology. "The positive recommendation for VAZKEPA in Spain is an important step for the thousands of cardiovascular patients who now have access to a new, innovative treatment option to reduce their cardiovascular risk based on the robust clinical data and evidence from the REDUCE-IT study," said Patrick Holt, President and CEO of Amarin. "Our team in Spain will now be laser-focused on supporting efforts to reach healthcare professionals and drive awareness and adoption of this important new treatment for patients. I look forward to our launch efforts to accelerate growth in this important market."

16:33 EDT BayFirst Financial names McKim next CFO of BayFirst National Bank - BayFirst Financial announced the appointment of Scott J. McKim as Executive Vice President and Chief Financial Officer CFO of BayFirst Financial Corp. and its wholly owned subsidiary, St. Petersburg, Fla.-based BayFirst National Bank.

16:30 EDT Rush Enterprises announces 3 for 2 stock split, 17c dividend - The Company's Board of Directors declared a three-for-two stock split with respect to both the Company's Class A and Class B common stock. The stock split will be effected in the form of a stock dividend payable on August 28, 2023, to shareholders of record as of August 7. Holders of the Company's common stock will receive an additional one-half share for each share of common stock held as of the record date. The stock split will increase the number of outstanding shares of Class A common stock from approximately 41,690,232 to approximately 62,535,348 and will increase the number of outstanding shares of Class B common stock from approximately 12,140,108 to approximately 18,210,161. Additionally, the Company's Board of Directors declared a cash dividend of 17c per share of Class A and Class B common stock, to be paid on September 22 to all shareholders of record as of September 7. "We remain dedicated to returning capital to our shareholders, and we are pleased to announce a post-stock split cash dividend of 17c per share. After the stock split, this represents a 21.4% increase in the quarterly cash dividend paid to our shareholders compared to the prior quarterly dividend," said W.M. "Rusty" Rush, Chairman, Chief Executive Officer and President of Rush Enterprises, Inc.

16:26 EDT Snap says 'focused' on investing 'heavily' in direct-response business - In its quarterly investor letter, Snap said, "Given the progress we have made with our ad platform, the leadership team we have built, the work we have done to reprioritize our cost structure, and the strength of our balance sheet, we believe we are well positioned to continue making progress on our top strategic priorities. As we move forward into Q3, we remain intently focused on investing in products and platforms to sustain community growth, investing heavily in our direct-response business to deliver measurable return on ad spend, and cultivating new sources of revenue to diversify our topline growth to build a more resilient business." Reference Link

16:22 EDT Northern Oil raises its FY23 production view to 96,000-100,000 Boe per day - Previously 91,000 to 96,000 Boe per day, "reflecting strong well performance, contributions from the Forge and Novo acquisitions and adjustments for a lower expected TIL count in 2023," the company said. The TIL count and cadence changes are driven by modifications to the drilling plan for the MPDC Mascot project and by price-driven deferrals from a large Williston Basin operating partner. The Company is also adjusting the corporate oil mix to account for the acquired volumes. The Company also is guiding to production expectations of 99,000 to 103,000 Boe per day for the third quarter of 2023, based on an August 15, 2023 closing date for the Novo acquisition. "NOG remains focused on maximizing returns on our assets," commented Nick O'Grady, NOG's Chief Executive Officer, "We fully support our operating partners and the decisions driving some changes to the 2023 plan. We expect these changes to benefit our shareholders through higher realized prices and by driving down costs. Well performance continues to exceed our internal estimates, which sets the stage for further capital efficient growth as we look toward 2024. Our updated guidance also highlights the continued path of reducing unit costs and improving margins."

16:21 EDT Chubb CEO says 'we had another simply outstanding quarter' - Evan Greenberg, Chairman and CEO of Chubb Limited, commented: "We had another simply outstanding quarter - in fact, a record, which contributed to a record six months. Our financial performance included double-digit premium revenue and earnings growth supported by world-class P&C underwriting results and an 85.4% combined ratio, record net investment income, and a doubling of our life earnings. For the quarter, core operating income and income per share were up 13.9% and 16.6%, respectively, and for the first six months, they were up 12.9% and 15.8%. Our operating earnings for the quarter topped $2 billion for the first time. We produced an annualized core operating ROE of 13.8%, with a return on tangible equity of 21%. Our exceptional underwriting performance was driven by strong P&C premium revenue growth, excellent current accident year underwriting margins with a record combined ratio of 83.3%, favorable prior period reserve development, and a moderate level of catastrophe losses. On the investment side, record adjusted net investment income was up $290 million, or 30.6%, over prior year. Our investment income run rate will continue to grow as we reinvest cash flow at higher rates and compound income. Our total company net written premium growth of 16.8% in constant dollars was balanced and broad-based, driven by double-digit growth in our commercial and consumer P&C businesses in North America and internationally, and 127.6% growth in our life business. The Global P&C constant dollar growth rate of 10.9% was the best we've seen in the last seven quarters. Global P&C premiums in North America grew 10.6%, with our consumer business up 10.8% and our commercial business up 10.5%, or 14% excluding financial lines. In our Overseas General division, premiums grew 10.9% in constant dollars, with strong growth of 17.4% in Asia and 10.5% in Europe. The level of rate increases overall in North America commercial P&C accelerated in the quarter to 8.7%, or 12.6% excluding financial lines, driven by increases in both property and casualty lines of business of 22% and 8.9%, respectively. Price increases, which take into account exposure, were even greater. We have a lot of momentum heading into the second half. As I look ahead, we remain confident in our ability to continue the pattern of growth in revenue and earnings, and, in turn, drive double-digit EPS growth."

16:18 EDT Matador sees Q3 average daily production 129.5K-131.5K BOE per day - Matador began 2023 operating seven drilling rigs in the Delaware Basin. Following the closing of the Advance acquisition on April 12, 2023, Matador continued operating the drilling rig that Advance had been operating. Near the end of June 2023, Matador released this eighth operated drilling rig and continued operating seven drilling rigs in the Delaware Basin. Matador currently plans to operate seven drilling rigs for the remainder of 2023. Not only is the release of the eighth drilling rig expected to save capital expenditures, but also Matador still expects to achieve its goals for oil and natural gas production and its goals for number of wells drilled and turned to sales in 2023. At July 25, 2023, the Company expects D/C/E capital expenditures for the third quarter of 2023 will be approximately $300 million and midstream capital expenditures to be approximately $90 million.

16:17 EDT Alphabet reports on impact of change in useful lives of equipment - Alphabet said: "In January 2023, we completed an assessment of the useful lives of our servers and network equipment and adjusted the estimated useful life of our servers from four years to six years and the estimated useful life of certain network equipment from five years to six years. This change in accounting estimate was effective beginning in fiscal year 2023, and the effect was a reduction in depreciation expense of $966M and $2.0B and an increase in net income of $752M and $1.5B, or 6c and 12c per basic and 6c and 12c per diluted share for the three and six months ended June 30, 2023, respectively."

16:13 EDT Snap falls 16% to $10.52 after Q2 earnings and guidance

16:12 EDT Middlesex Water plant to treat ground water for PFAS compounds in service - Middlesex Water Company has announced that construction of an upgraded treatment plant at its Park Avenue wellfield in South Plainfield, New Jersey to treat Peruorooctanoic Acid PFOA, is now constructed and in service. The plant is treating groundwater in compliance with all state and federal drinking water standards. In 2021, the New Jersey Department of Environmental Protection NJDEP adopted a new regulation, or Maximum Contaminant Level for one of the more prevalent per-and polyfluoroalkyl substances compounds, PFOA. While the drinking water delivered by Middlesex met all existing regulatory standards at the time, when the new MCL became effective, the Park Avenue Plant initially exceeded the new PFOA standard. The Company suspended use of the wellfield once it was able to switch to alternate sources of supply in November 2021. These alternate sources of supply helped ensure water delivered, from that time forward, was in compliance with all drinking water standards.

16:11 EDT Intel, Ericsson expand collaboration over next-gen optimized 5G infrastructure - Intel (INTC) announced a strategic collaboration agreement with Ericsson (ERIC) to utilize Intel's 18A process and manufacturing technology for Ericsson's future next-generation optimized 5G infrastructure. As part of the agreement, Intel will manufacture custom 5G SoCs (system-on-chip) for Ericsson to create highly differentiated leadership products for future 5G infrastructure. Additionally, the companies will expand their collaboration to optimize 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost for Ericsson's Cloud RAN (radio access network) solutions to help communications service providers increase network capacity and energy efficiency while gaining greater flexibility and scalability. "As our work together evolves, this is a significant milestone with Ericsson to partner broadly on their next-generation optimized 5G infrastructure. This agreement exemplifies our shared vision to innovate and transform network connectivity, and it reinforces the growing customer confidence in our process and manufacturing technology," said Sachin Katti, senior vice president and general manager of the Network and Edge group at Intel. "We look forward to working together with Ericsson, an industry leader, to build networks that are open, reliable and ready for the future."

16:09 EDT Cal-Maine Foods says egg prices returned to more normal levels - The company states: "We are proud of our performance over the past year as we demonstrated solid execution of our organic growth strategy in a dynamic market environment. Despite ongoing uncertainties related to HPAI and other macroeconomic concerns, we remained focused on managing our operations as efficiently and safely as possible. We have continued to deliver against our key performance metrics, and we commend the work of our managers and employees for their dedication and continued support of our valued customers. Across our operations, we have a shared commitment to our mission to be the most reliable and sustainable producer of fresh shell eggs and egg products. While egg prices were higher during most of fiscal 2023 due primarily to the impact of HPAI and higher grain and other input costs, they have returned to pricing levels more in line with historic norms. Moving forward, we believe that the demand for affordable food choices will continue to grow. As the largest producer and distributor of fresh shell eggs, we are well positioned to support this need in more communities. Eggs offer a great nutritional value with high quality protein and essential vitamins and minerals for healthy living such as choline, vitamin B12 and iodine. Cal-Maine Foods' proven operating model and differentiated product mix continue to support our ability to meet changing customer demand and extend our market reach. Importantly, we have the financial strength to support our growth strategy, which includes acquisitions and organic growth, and we look forward to the opportunities ahead for Cal-Maine Foods in fiscal 2024."

16:08 EDT TLG Acquisition One holders approve business combination with Electriq Power - TLG Acquisition One Corp. announced that its stockholders voted to approve the previously announced business combination (the "Business Combination") with Electriq Power, Inc. ("Electriq") at TLG's special meeting of stockholders in lieu of the 2023 annual meeting of stockholders held on July 25, 2023 (the "Special Meeting"). Over 98% of the votes cast at the Special Meeting were cast in favor of the approval of the Business Combination. TLG stockholders also voted to approve all other proposals presented at the Special Meeting. TLG plans to file the results of the Special Meeting, as tabulated by the inspector of election, with the Securities and Exchange Commission (the "SEC") on a Form 8-K. The Business Combination is expected to close on Monday, July 31, 2023, subject to customary closing conditions. TLG estimates that the redemption price of TLG's Class A common stock, par value $0.0001 per share, in connection with the Business Combination to be $10.63 per share. Additionally, TLG today announced that it has cancelled the special meeting of stockholders previously scheduled for July 27, 2023 (the "Extension Meeting") to, among other things, vote upon a proposal to extend the date by which TLG could complete a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. TLG determined that the Extension Meeting is no longer necessary since the Business Combination is expected to close prior to August 1, 2023, its current business combination deadline.

16:08 EDT Visa reports Q3 transactions processed $54B - Reports Q3 cross-border volumes at constant currency up 17%.

16:07 EDT Infinity Pharmaceuticals to reduce staff by 78%, to seek strategic transaction - Infinity Pharmaceuticals announced a series of actions designed to reduce the Company's burn rate and enhance our ability to maximize value of eganelisib, following the termination of its previously announced merger agreement with MEI Pharma, Inc. The Company continues to believe, based on the data generated to date, that eganelisib offers a near-term value creation opportunity that would be attractive to potential third-party acquirers. Infinity has advanced eganelisib toward the initiation of a planned global Phase 2 clinical trial in head and neck squamous cell carcinoma, and, following FDA feedback, has submitted the final protocol to the FDA. Infinity's Board of Directors intends to seek a strategic transaction to maximize eganelisib's potential and intends to retain SSG Capital Advisors LLC, an independent investment bank, to lead this process. In parallel, in order to reduce ongoing expenditures Infinity is implementing the following measures: A reduction in force of 21 employees or approximately 78% of the current workforce. A reduction in the size of the Board from eight members to five, with Dr. Brian Schwartz, Dr. Sam Agresta, and Mr. Sujay Kango departing. The remaining five members of the Board have agreed to serve without compensation for the remainder of their Board service. The reduction in force and other value preservation measures are expected to result in a one-time charge of $3.4 million in severance and restructuring costs in the third quarter of 2023.

16:05 EDT Alphabet CFO says results reflect continued resilience in Search - Ruth Porat, CFO of Alphabet and Google, said: "Our financial results reflect continued resilience in Search, with an acceleration of revenue growth in both Search and YouTube, as well as momentum in Cloud. We continue investing for growth, while prioritizing our efforts to durably reengineer our cost base company-wide and create capacity to deliver sustainable value for the long term."

16:05 EDT NexTier Oilfield sees Q3 CapEx $85M - "Given the pending merger with Patterson-UTI, we will not provide detailed financial guidance. On activity, we anticipate we could see our deployed fleet count fall by as many as 3 fleets by the end of the third quarter, and we also expect to see increased whitespace, with our average pumping hours per fleet also expected to decline slightly. For the third quarter of 2023, we expect capital expenditures will be down, sequentially, to $85 million. We expect to reduce capital expenditures further in the fourth quarter. Free cash flow should be strong again and we expect that we will exceed our target of zero net debt by the end of the third quarter." Drummond concluded, "We view the current slowdown in industry activity as transitory, and by 2024, we see a path for US land completion activity to recover to levels that we saw in the first quarter of this year. Considering our view that newbuilds have been insufficient to entirely replace attrition, we believe frac equipment could once again be the bottleneck to US oil and gas production growth by next year. We have no intention to accelerate the depreciation of our equipment to hold work in the near-term, and as such, we will use any downtime as an opportunity to invest to upgrade and fully maintain our fleet to ensure we are prepared for a recovery."

16:05 EDT Alphabet reports Q2 Google advertising revenue $58.14B vs. $56.29B last year - Reports Q2 YouTube ads revenue $7.67B vs. $7.34B in same quarter of prior year. Reports Q2 Google Search and other revenue $42.63B vs. $40.69B a year ago. Reports Q2 total Traffic Acquisition Costs $12.54B vs. $12.21B a year ago.

16:04 EDT Microsoft reports Q4 Productivity and Business Processes revenue up 10% - Microsoft said Revenue in Productivity and Business Processes was $18.3B and increased 10%, with the following business highlights: Office Commercial products and cloud services revenue increased 12% driven by Office 365 Commercial revenue growth of 15%; Office Consumer products and cloud services revenue increased 3% and Microsoft 365 Consumer subscribers grew to 67.0M; LinkedIn revenue increased 5%; Dynamics products and cloud services revenue increased 19% driven by Dynamics 365 revenue growth of 26%.

16:03 EDT LPL Financial to acquire Crown Capital Securities, no terms - LPL Financial announced that the firm has entered into a definitive purchase agreement to acquire the wealth management business of Crown Capital Securities, headquartered in Orange County, California. Crown supports approximately 260 financial advisors, who serve approximately $6.5 B of advisory and brokerage assets. Established in 1999, Crown was founded on the philosophy that financial advisors should have the freedom to build a practice on their terms. Crown advisors offer their clients customized, high-touch services such as investment management, estate planning, risk management, education planning, corporate benefits, full-service brokerage and alternative investments. "Through this agreement, Crown advisors will maintain the independence and freedom to innovate, which they have valued at Crown, while enjoying access to LPL's industry-leading technology and integrated advisor platform," said Jonathan French, President, Crown Capital. "Additionally, advisors will have the operational support to help their practices thrive, and enhance their long-standing and personal client relationships." The purchase agreement was signed on July 21, and the transaction is expected to close in early 2024, subject to receipt of regulatory approval and other customary closing conditions.

16:00 EDT PacWest Bancorp trading halted, news pending

15:51 EDT Redwire selected for $12.9M NASA Tipping Point award - Redwire has been selected for a $12.9M NASA Tipping Point award to prototype a first-of-its-kind manufacturing technology intended to build critical infrastructure on the surface of the Moon, including landing pads, roads and foundations for habitats. This technology could enable robust construction on the lunar surface to advance human and robotic operations, paving the way for a sustainable human presence and a dynamic lunar economy.

15:43 EDT Enzo Biochem jumps over 10% after announcing asset sale to Labcorp - Shares of clinical lab, and life sciences company Enzo Biochem are rallying approximately 10% or 14c a share to $1.50 per share on Tuesday after announcing earlier on Tuesday that it has completed the previously announced transaction to sell substantially all of the assets located in the New York metropolitan region used in the operation of Enzo Clinical Labs to Labcorp for an aggregate purchase price of $113,250,000 in cash, subject to customary closing adjustments. In accordance with the sale, Enzo Biochem will cease its clinical laboratory operations. "The closing of this asset sale demonstrates our commitment to enhancing shareholder value," said Hamid Erfanian, CEO of Enzo Biochem. "With the closing of this transaction, Enzo Biochem would like to express its profound gratitude to the generations of employees and physician partners who have dedicated themselves to providing the highest level of care and service to our patients. We are confident that Labcorp will continue to enrich and enhance the level of care and service that our physicians and patients have come to expect."

15:20 EDT The Council of the EU adopts new rules intended to make EV charging convenient - The Council of the EU adopts new law for more recharging and refuelling stations across Europe: "More recharging and refuelling stations for alternative fuels will be deployed in the coming years across Europe enabling the transport sector to significantly reduce its carbon footprint following today's adoption on the alternative fuel infrastructure regulation or AFIR. Raquel Sanchez Jimenez, Spanish Minister of Transport, Mobility and Urban Agenda said, "The new law is a milestone of our 'Fit for 55' policy providing for more public recharging capacity on the streets in cities and along the motorways across Europe. We are optimistic that in the near future, citizens will be able to charge their electric cars as easily as they do today in traditional petrol stations." The text of the regulation provides for specific deployment targets that will have to be met in 2025 or 2030, in particular: from 2025 onwards, fast recharging stations of at least 150kW for cars and vans need to be installed every 60 km along the EU's main transport corridors, the so-called 'trans-European transport or TEN-T network' recharging stations for heavy-duty vehicles with a minimum output of 350kW need to be deployed every 60 km along the TEN-T core network, and every 100 km on the larger TEN-T comprehensive network from 2025 onwards, with complete network coverage by 2030 hydrogen refuelling stations serving both cars and lorries must be deployed from 2030 onwards in all urban nodes and every 200 km along the TEN-T core network maritime ports welcoming a minimum number of large passenger vessels, or container vessels, must provide shore-side electricity for such vessels by 2030 airports must provide electricity to stationary aircraft at all gates by 2025, and at all remote stands by 2030 users of electric or hydrogen-fuelled vehicles must be able to pay easily at recharging or refuelling points with payment cards or contactless devices and without a need for a subscription and in full price transparency operators of recharging or refuelling points must provide consumers full information through electronic means on the availability, waiting time or price at different stations," said the statement in part. Publicly traded companies in the space include Ford (F), General Motors (GM), Honda (HMC), Mercedes-Benz Group (DDAIF), Nissan (NSANY), Stellantis (STLA), Tesla (TSLA), Toyota (TM) and Volkswagen (VWAGY). Reference Link

15:05 EDT Karyopharm presents updated analyses from SIENDO study of selinexor - Karyopharm Therapeutics announced the presentation of updated exploratory subgroup analyses from the SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the virtual American Society of Clinical Oncology, or ASCO, Plenary Series. "The primary analysis of the Phase 3 SIENDO study of selinexor maintenance therapy in advanced or recurrent endometrial cancer showed improvements in median progression-free survival - PFS - for the intent-to-treat - ITT - population but were not clinically meaningful. However, an exploratory analysis of a pre-specified subgroup of patients with TP53 wild-type endometrial cancer showed a promising efficacy signal. In the SIENDO study, 263 patients were randomly assigned, with 174 patients allocated to the selinexor arm and 89 patients to the placebo arm. One hundred and thirteen patients with TP53 wild-type endometrial cancer were randomized to receive selinexor vs placebo as maintenance therapy. As of the March 30, 2023 data cut-off date, and a median duration of follow-up of 25.3 months, selinexor-treated patients with TP53 wild-type endometrial cancer had a median PFS of 27.4 months compared to 5.2 months for patients with TP53 wild-type endometrial cancer receiving placebo. Additionally, median PFS was not reached for selinexor-treated TP53 wild-type MSS - pMMR - endometrial cancer patients compared to 4.9 months for TP53 wild-type MSS - pMMR - endometrial cancer patients treated with placebo. No new safety signals were identified as of the last data cut-off date on March 30," the company stated. "The updated results from SIENDO suggest that selinexor may have the potential to prolong systemic therapy response in patients whose disease is TP53 wild-type. Particularly encouraging are the data observed in the subgroup of patients whose disease are both TP53 wild-type and MSS. We are encouraged by the updated results from this study as it further strengthens the rationale for our ongoing EC-042 Phase 3 study," said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm.

14:46 EDT Banc of California rises, PacWest falls after WSJ report of merger talks - Shares of Banc of California (BANC) remain up about 7% to $14.06 after The Wall Street Journal said the bank is in advanced talks to buy PacWest Bancorp (PACW) and a deal could be announced as soon as today, when both banks are scheduled to report results. Shares of PacWest are down about 10% to $9.44 following the Journal's report.

14:42 EDT PacWest falls 10% after WSJ says Banc of California in advanced talks to buy

14:30 EDT Intel up 1% to $34.09 after report of price increases

14:15 EDT Surf Air Mobility announces registration statement declared effective by SEC - Surf Air Mobility, which identifies itself as "a regional air travel company aiming to sustainably connect the world's communities," announced that its registration statement on Forms S-1 and S-4 was declared effective by the U.S. Securities and Exchange Commission on July 25. Surf Air Mobility anticipates that its common stock will begin trading on the New York Stock Exchange under the ticker symbol "SRFM" on July 27, the company noted.

13:32 EDT Companhia Parana trading resumes

13:08 EDT Companhia Parana trading halted, news pending

12:31 EDT Arconic shareholders approve $30 per share acquisiotn by Apollo - Arconic (ARNC) announced that its shareholders have voted to approve the company's pending acquisition by funds managed by affiliates of Apollo (APO). Under the terms of the merger agreement, Arconic shareholders will receive $30.00 per share in cash for every share of Arconic common stock they own immediately prior to the effective time of the merger. Assuming timely satisfaction of necessary closing conditions, the transaction is expected to close in Q3.

12:11 EDT UPS confirms tentative labor agreement with Teamsters - UPS and the International Brotherhood of Teamsters, the union representing about 330,000 UPS employees in the U.S., have reached a tentative collective bargaining agreement. "Together, we reached a win-win-win agreement on the issues that are important to Teamsters leadership, our employees and to UPS and our customers," said Carol Tome, UPS CEO. "This agreement continues to reward UPS's full- and part-time employees with industry-leading pay and benefits while retaining the flexibility we need to stay competitive, serve our customers and keep our business strong." The five-year agreement covers U.S. Teamsters-represented employees in small-package roles and is subject to voting and ratification by union members.

12:00 EDT TLG Acquisition One falls -17.7% - TLG Acquisition One is down -17.7%, or -$1.67 to $7.74.

12:00 EDT Zevia falls -23.6% - Zevia is down -23.6%, or -$1.00 to $3.23.

12:00 EDT Packaging Corp. rises 10.3% - Packaging Corp. is up 10.3%, or $14.33 to $153.00.

11:59 EDT UPS up 2% to $191.23 after Teamsters union agrees to contract

11:55 EDT Teamsters union announces tentative agreement with UPS - The Teamsters union said via Twitter that it has reached "the most historic tentative agreement for workers in the history of UPS, protecting and rewarding more than 340,000 UPS Teamsters nationwide." The contract raises wages for all workers, creates more full-time jobs, and includes dozens of workplace protections and improvements, the union said. Reference Link

11:51 EDT Starboard's Smith says 'pretty excited' about AI opportunity at Salesforce

11:50 EDT RTX cuts FY23 cash flow view by $500M to $4.3B - The company said earlier on its Q2 earnings conference call that the reduction is primarily to reflect the developments at Pratt & Whitney. CEO Greg Hayes said the quality issue is going to be "expensive" to fix.

11:47 EDT Talks with Algonquin Power have been 'very constructive,' Starboard's Smith says

11:46 EDT Starboard's Smith sees 'extra upside' if Algonquin monetized water utility - Jeff Smith, Chief Executive Officer and Chief Investment Officer of Starboard Value, is being interviewed on CNBC.

11:38 EDT RTX sinks after Pratt & Whitney finds 'rare condition' in powder metal - Shares of RTX are moving lower after the company disclosed in its Q2 earnings report that Pratt & Whitney determined a "rare condition in powder metal used to manufacture certain engine parts will require accelerated fleet inspection." As a result, the business anticipates that a significant portion of the PW1100G-JM engine fleet, which powers the A320neo, will require accelerated removals and inspections within the next nine to twelve months, including approximately 200 accelerated removals by mid-September of this year. "The business is working to minimize operational impacts and support its customers," RTX said. The shares are down 14% to $83.40 in midday trading.

11:22 EDT Redwire, Lockheed Martin named among NASA partners for moon exploration - NASA announced it has selected 11 U.S. companies to develop technologies that could support long-term exploration on the Moon and in space for the benefit of all. The technologies range from lunar surface power systems to tools for in-space 3D printing, which will expand industry capabilities for a sustained human presence on the Moon through Artemis, as well as other NASA, government, and commercial missions. The selected technologies support infrastructure and capabilities in space and at the Moon. Six of the selected companies are small businesses. The awarded companies, their projects, and the approximate value of NASA's contribution are: Astrobotic Technology of Pittsburgh, $34.6M; Big Metal Additive of Denver, $5.4M; Blue Origin of Kent, Washington, $34.7M; Freedom Photonics of Santa Barbara, California, $1.6M; Lockheed Martin of Littleton, Colorado, $9.1M; Redwire of Jacksonville, Florida, $12.9M; Protoinnovations of Pittsburgh, $6.2M; Psionic of Hampton, Virginia, $3.2M; United Launch Alliance of Centennial, Colorado, $25M; Varda Space Industries of El Segundo, California, $1.9M; and Zeno Power Systems of Washington, $15M. Reference Link

11:08 EDT Cintas boosts quarterly dividend 17% to $1.35 from $1.15 per share - Cintas approved a quarterly cash dividend of $1.35 per share of common stock payable on September 15, to shareholders of record at the close of business on August 15. This represents a 17.4% increase compared to last fiscal year's dividend. "Cintas has a strong record of returning capital to its shareholders and has consistently raised its dividend each year since Cintas' initial public offering 40 years ago in 1983," the company said in a statement.

11:06 EDT Humanigen plunges after warning on inability to continue as going concern - In a regulatory filing earlier, Humanigen stated: "The company's negotiations with a privately held biopharmaceutical company relating to a proposed business combination, as disclosed in the company's Quarterly Report on Form 10-Q filed on May 15, 2023, have ended without execution of a definitive agreement. In addition, the company has been unsuccessful in its attempt to identify and complete another strategic or equity financing transaction in the first half of 2023 on terms sufficient to enable the company to regain compliance with applicable Nasdaq listing requirements within the extended compliance period of August 21, 2023. The company further has been unsuccessful in raising debt or equity financing in sufficient amounts and with acceptable terms to fund the company's operations going forward. In light of these developments and the matters discussed above under Item 3.01, on July 21, 2023, the company notified the Nasdaq Hearings Panel that it does not expect to be able to demonstrate compliance with all applicable criteria for listing on The Nasdaq Capital Market by August 21, 2023, including the $1.00 minimum bid price per share requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the $35 million market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2). As a result, the company received a letter on the evening of July 24, 2023 indicating that the Panel will delist the shares of the company from the Nasdaq Capital Market and trading in the company shares will be suspended from Wednesday, July 26, 2023. The shares will commence trading on the OTC Pink Market. The suspension from trading and delisting from the Nasdaq Capital Market likely would adversely affect the liquidity of the company's common stock and its ability to raise additional capital. In light of the above, and the company's limited cash and cash equivalents, the company anticipates that it will not be able to continue as a going concern and is exploring all restructuring options, which may include commencing a bankruptcy or other insolvency proceeding sometime in the third quarter of 2023. In that regard, the company is evaluating term sheets relating to potential sales of assets in a bankruptcy proceeding. Given the company's lack of liquidity, any such bankruptcy filing may result in a complete or substantial loss of value for holders of our common stock." In morning trading, Humanigen shares have fallen 14c, or 74%, to 5c.

11:04 EDT Beckman Coulter receives FDA clearance for DxC 500 AU Chemistry Analyzer - Beckman Coulter Diagnostics received FDA clearance for its new DxC 500 AU Chemistry Analyzer, an automated chemistry analyzer, expanding the company's clinical chemistry offering and demonstrating ongoing commitment to product innovation in the in vitro diagnostic industry. Designed for small-to-medium-sized laboratories, the DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to optimize laboratory workflows and support critical clinical decisions.

11:02 EDT Mattel, Warner Bros. Discovery Global Consumer Products renew licensing deal - Mattel renewed its licensing agreement with Warner Bros. Discovery Global Consumer Products. Mattel will continue as a Warner Bros.' toy licensee for the preschool, plush, dolls, vehicles, games, and novelty toy categories, developing and marketing products for more than 50 Warner Bros. Discovery brands and franchises including DC Universe, DC Super Friends, "Batwheels," Harry Potter, Fantastic Beasts, FRIENDS, Seinfeld, and Ted Lasso, among others.

10:37 EDT Nymox reports 'statistically significant' results from NX03-0040 study - Nymox Pharmaceutical Corporation announced new long-term clinical trial results from the company's 146 patient NX03-0040 NYMOZARFEX U.S. study for low grade localized prostate cancer. New long-term follow-up data from the prospective randomized clinical trial of NYMOZARFEX for low grade early prostate cancer has indicated that there is strong statistically significant benefit from the treatment compared to controls when all available patient outcomes were included from 18 months to as long as up to greater than10 years after treatment. These additional 5 to 10-year data points add to the 5-year data that was published in the peer review World Journal of Urology in 2020, Nymox said. The outcome comparisons showed greatly reduced percentages of subjects treated with NYMOZARFEX who had progressed by either cancer grade worsening or by prostate cancer surgery, radiotherapy, or chemotherapy; and which remained overall strongly statistically significant compared to the study's randomized controls. Study NX03-0040 was undertaken starting in 2012 at investigational sites across the U.S. with 146 men with the biopsy confirmed diagnosis of Grade Group1 prostate cancer. NYMOZARFEX was administered by a single painless injection directly into the prostate in a relatively simple procedure requiring several minutes or less in an office setting without sedation or anesthesia, and guided by routine ultrasound. NYMOZARFEX was injected into the area of the prostate where the cancer was previously detected prior to enrollment in NX03-0040. The patients were then biopsied after 6 weeks and then every 18 months, along with serial PSA measurements and long-term follow-up.

10:28 EDT Symetryx ups Check-Cap offer to $4.60 per share, urges engagement - Symetryx announced an increase in price per share for its non-binding proposal to acquire common shares of Check-Cap. Symetryx revised the on-binding proposal to pay $4.60 per Check-Cap common share in cash, up from its prior offer of $4.35 per share. Symetryx said it has continued buying common shares of Check in the market and has increased its position following its July 18 press release. To date, the Check board "has not responded to Symetryx's request to communicate with us and allow us to begin due diligence as outlined in the July 18 Press Release," the company said in a statement. Symetryx repeats its request to the Check board to "immediately engage in communications with the Symetryx Board of Directors and executive management. If the Check Board does not engage in communications with Symetryx regarding our non-binding offer, Symetryx may consider commencing a tender offer directly to Check shareholders in accordance with U.S. federal securities laws, rules, and regulations." Symetryx said its non-binding proposal is "contingent upon a number of conditions," including immediate engagement by and with the Check board, completion of satisfactory due diligence, and obtaining satisfactory financing arrangements. It urges the Check board "to enter a non-disclosure agreement with Symetryx and allow us to commence due diligence as soon as possible." Symetry adds, "We may withdraw our non-binding proposal at any time without notice. We believe that the Symetryx non-binding proposal might create substantial value for Check shareholders."

10:24 EDT S&T Bancorp appoints Michael Golden as COO - S&T Bancorp announced that Michael Golden joined the company as executive vice president, COO, effective July 24, 2023. Golden will oversee the functional activities in support of the Bank's strategic objectives, ensuring proper operational controls, administrative practices, systems and customer solutions are in place to effectively grow the organization and maximize operating efficiency. He also serves as a member of the senior leadership team. Golden has spent the majority of his 26-year professional career in the banking industry, most recently serving as head of digital and business technology at PNC Bank where he led the development and execution of key objectives including digital transformation and reorganization of business technology strategy and product development for PNC's asset management group.

10:12 EDT Red White & Bloom Brands adds debtor-in-possession financing for Aleafia - Red White & Bloom Brands (RWBYF) provides an update on the indebtedness of Aleafia Health (ALEAF) and certain of its affiliates in connection with the loan agreement made as of December 24, 2021, as amended on March 28, 2022, June 17, 2022, April 26, 2023, May 15, 2023, and May 31, 2023 and assigned to RWB on June 6, 2023. Aleafia announced that it has received an order from the Ontario Superior Court of Justice under the Companies' Creditors Arrangement Act, in order to restructure its business and financial affairs. The Initial Order approved, among other things, debtor-in-possession financing to be provided by RWB to fund the Aleafia CCAA Proceedings and other short-term working capital requirements pursuant to a term sheet between RWB and Aleafia dated July 24, 2023. Under the Aleafia DIP Term Sheet, RWB agreed to advance DIP Financing in the amount of $6,600,000. The continued availability of the DIP Loan is conditional upon, among other things, certain conditions being satisfied, including the Initial Order remaining in effect. A copy of the DIP Term Sheet will be filed on SEDAR+. As noted in the joint press release of RWB and Aleafia dated July 14, 2023, Aleafia was in breach of certain covenants under the Aleafia Senior Secured Loan Agreement, and the previously announced Proposed Transaction between the parties had been mutually terminated. RWB did not waive any outstanding breaches and reserved all of its rights and remedies under the Aleafia Senior Secured Loan Agreement. RWB also provided a series of extensions and other accommodations under the Aleafia Senior Secured Loan Agreement. After the close of markets yesterday, in light of Aleafia's financial position, RWB issued demand letters and notices to enforce security under Section 244 of the Bankruptcy and Insolvency Act and provided Aleafia with the aforementioned DIP Loan to allow Aleafia to proceed with the Aleafia CCAA Proceedings.

10:07 EDT BAE Systems awarded $15M contract from U.S. Navy - BAE Systems has received a $15M contract from the U.S. Navy to deliver its next-generation digital interrogator for maritime vessels. The interrogator will have advanced capabilities-providing time-critical insights that reduce friendly fire incidents and support mission success in hostile environments. BAE Systems' modernized AN/UPX-50 Digital Interrogator will provide a common modular design and open system architecture. Its design enables the rapid integration of new technology within the existing footprint through software updates instead of hardware configuration.

10:00 EDT RTX falls -13.8% - RTX is down -13.8%, or -$13.37 to $83.64.

10:00 EDT Zevia falls -25.5% - Zevia is down -25.5%, or -$1.08 to $3.15.

10:00 EDT Posco rises 8.4% - Posco is up 8.4%, or $9.94 to $128.13.

09:58 EDT Rimini Street to appeal federal court ruling in Oracle litigation - Rimini Street (RMNI) issued the following statement in response to the July 24, 2023 Order issued by the U.S. Federal Court for the District of Nevada in the Oracle (ORCL) v. Rimini Street litigation: "Rimini Street and Oracle have been in litigation for more than 13 years. While the U.S Federal Courts confirmed long ago that third-party software support is legal, the Rimini II litigation is related to the manner in which Rimini Street provides support services for certain Oracle product lines. Rimini Street is not prohibited from providing support or services for any Oracle products. Just days before the jury trial was set to begin in the Rimini II litigation, Oracle withdrew all its claims against Rimini Street and its CEO, Seth A. Ravin, for monetary relief of any kind under any legal theory in the litigation. Rimini Street's remaining counterclaims and Oracle's remaining claims seeking only equitable relief were tried before the Court as a non-jury trial that started on November 29, 2022 and ended on December 15, 2022. The Court issued its Order on July 24, 2023. Rimini Street is pleased that it prevailed in Court on many significant legal points, including the following: Oracle brought infringement claims seeking injunctive relief as to five products lines and failed as to four of them. The Court entered a declaratory judgment of non-infringement for EBS software. The Court rejected Oracle's argument that Oracle's license agreements, or the Court's prior orders, prevent Rimini Street from documenting its own "know how" and code in technical specifications used with multiple clients. The Court held that the pertinent software licenses do not prohibit Oracle's customers from hiring a third party like Rimini Street to perform updates or fixes to the same extent the Oracle customer could under the pertinent license. In addition to the key legal points where Rimini Street prevailed in Court, Rimini Street respectfully disagrees with several conclusions, findings, comments and rulings of the Court and plans to file an appeal. Over the long history of litigation with Oracle, Rimini Street has filed multiple legal appeals, and to-date Rimini Street has prevailed to some degree in every appeal to the Ninth Circuit of the U.S. Court of Appeals and even achieved a rare, unanimous victory in the U.S. Supreme Court against Oracle. Oracle was even ordered through appeals to refund Rimini Street a total of more than $34 million."

09:47 EDT RTX falls -12.8% - RTX is down -12.8%, or -$12.38 to $84.64.

09:47 EDT Zevia falls -21.5% - Zevia is down -21.5%, or -91c to $3.32.

09:47 EDT Nio rises 7.9% - Nio is up 7.9%, or 93c to $12.66.

09:44 EDT Biden announces rule to strengthen mental, physical health parity requirements - President Biden is announcing "new actions that would improve and strengthen mental health parity requirements and ensure that more than 150M Americans with private health insurance can better access mental health benefits under their insurance plan." The proposed rule reinforces MHPAEA's fundamental goal of ensuring that families have the same access to mental health and substance use benefits as they do physical health benefits. And it would make it easier to get in-network mental health care and eliminate barriers to access that keep people from getting the care they need, when they need it. Specifically, the proposed rule would require health plans to make changes when they are providing inadequate access to mental health care. The proposed rule would also make clear that health plans need to evaluate the outcomes of their coverage rules to make sure people have equivalent access between their mental health and medical benefits. This includes evaluating the health plan's actual provider network, how much it pays out-of-network providers, and how often prior authorization is required and the rate at which prior authorization requests are denied. Additionally, the proposed rule will provide specific examples that make clear that health plans cannot use more restrictive prior authorization, other medical management techniques, or narrower networks that make it harder for people to access mental health and substance use disorder benefits than their medical benefits. Under the proposed rule, health plans must use similar factors in setting out-of-network payment rates for mental health and substance use disorder providers as they do for medical providers. When MHPAEA was first enacted, it did not require non-federal governmental health plans, like those offered to state and local government employees, to comply with its requirements. The proposed rule would close that loophole and codify Congressional changes made to MHPAEA by requiring more than 200 additional health plans to comply with MHPAEA, providing critical protections to 90,000 consumers. In addition to announcing the proposed rule, the President also announced the Administration's intention to issue a request for information on how it can best work with states to ensure compliance with MHPAEA's critical protections for the millions of Medicaid beneficiaries enrolled in private Medicaid health plans. Publicly traded companies in the telehealth space include Teladoc (TDOC), Amwell (AMWL), Amdocs (DOX), and 1Life Healthcare (ONEM).Reference Link

09:30 EDT Cosmos Health provides updates on recent developments - Cosmos Health provided an update on recent developments, reaffirming the management team's belief and commitment to future prospects, and highlighting CEO Greg Siokas' participation in all capital raises since inception. The Company maintains a robust balance sheet with negligible debt and a strong, diversified asset base, including tangible assets such as unencumbered freehold properties as well as machinery and equipment with a fair market value in excess of $12 million. Additionally, among other things, it holds a highly valuable Good Manufacturing Practices icense, allowing it to manufacture medicines within the European Union, which will play an increasingly important role in the future, and owns a proprietary portfolio of branded nutraceuticals with unique formulations. The management team reiterates its belief in Cosmos Health's attractive growth prospects and commitment to profitability. This commitment is driven by several factors, including, among others, the integration and development of recently announced acquisitions, future potential acquisitions, notable progress in R&D with products advancing through various stages, including an obesity and weight management product in clinical trials, and constant growth of its nutraceutical brands, Sky Premium Life and Mediterranation, taking advantage of its expanding infrastructure of facilities worldwide, as well as leveraging its new brands inherited via the acquisition of Cana Laboratories, which include Eleon Cosmetics, C-Sept, and bio-bebe. On July 21, 2023, the Company raised gross proceeds of approximately $5.25 million, before deducting fees and other estimated expenses, from a registered direct offering and concurrent private placement. The Company expects to use the net proceeds from the offering for working capital, general corporate purposes, closing previously announced acquisitions and funding future potential acquisitions. While the offering was at a lower valuation than originally envisaged by the Company's board, it served certain important strategic objectives. In addition to allowing the Company to raise valuable capital, most importantly, it also resolved several legacy issues stemming from previous financing activities. Specifically, the offering successfully addressed a longstanding limitation, removing the right of participation from multiple investors. This streamlined approach replaces the more complex situation that previously entailed involvement from multiple investors. As a result, in the latest offering, only one party participated, a multi-billion-dollar fund with a strong specialization in the healthcare space, demonstrating confidence in the Company's growth prospects, management team, and strategy. Going forward, this essentially provides a "clean slate" approach for future initiatives. Management is of the opinion that this outcome provides a more sustainable platform to capitalize on future opportunities from investors who have a longer-term outlook on the Company, including strategic investors who are more knowledgeable within the healthcare space. So far in 2023, CEO Greg Siokas has invested approximately $450,000 in the aforementioned offering. He has also invested approximately $400,000 to acquire Cosmos Health shares in several private transactions between April and June 2023, bringing his total investments to approximately $850,000 year-to-date. Mr. Siokas has no intention of selling any shares. Additionally, since the inception of Cosmos Health, Mr. Siokas has demonstrated unwavering commitment by investing over $15 million in the Company. He has consistently and actively participated in all capital raises, spanning a range of prices, including $2.48 per share, $11.5 per share, and even more than $100 per share, while also waiving his right to warrants twice, at $11.5 per share and $2.48 per share, underscoring his dedication to supporting the Company throughout its journey and achieving its long-term objectives. Mr. Siokas continues to be the largest shareholder of the Company. Management is exploring several value enhancement initiatives, as it believes that its share price has not responded appropriately to a series of positive events year-to-date.

09:27 EDT Verizon does not see big free phone promotions returning - Says will continue to be financially disciplined.

09:22 EDT Euroseas announces new charters for two containerships Rena P, Emmanual P - Euroseas announced a mutual agreement to terminate the current charters for its container vessels M/V Rena P and M/V Emmanuel P, while concurrently fixing the vessels on new charters for $21,000 per vessel per day. Specifically: The Company agreed to terminate the current charter of M/V Rena P, a 4,250 TEU vessel built in 2007; which was originally expiring in February 2025 earning a rate of $20,250/day until April 2024 and, subsequently, a rate based on the CONTEX index with a floor of $13,000 and a ceiling of $21,000 per day. Contemporaneously with the termination, the Company has entered into a time charter contract for a minimum period of twenty to a maximum period of twenty-four months at the option of the charterer, at a gross daily rate of $21,000. The new charter will commence in August 2023, following the termination of its current charter. Similarly, the Company agreed to terminate the current charter of M/V Emmanuel P, a 4,250 TEU vessel built in 2005, which was originally expiring in March 2025 at a rate of $19,000/day. Contemporaneously with the termination, the Company has entered into a new time charter contract for a minimum period of twenty to a maximum period of twenty-four months at the option of the charterer, at a gross daily rate of $21,000. The new charter will commence in August 2023, following the termination of its current charter.

09:17 EDT Illumina, Pillar Biosciences announce partnership - Illumina and Pillar Biosciences announced a strategic partnership to make Pillar's suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products. The agreement will result in an unprecedented offering of complementary next-generation sequencing solutions that will enhance the efficiency, accuracy, and cost-effectiveness of oncology testing through advanced sequencing techniques, improving patient access to personalized cancer treatment options. Pillar's suite of oncology assays can be used on any of Illumina's sequencers. Assay offering will depend on the region. Commercial availability of Pillar's assays through Illumina is set to begin this month.

09:15 EDT Goodyear Tire announces cooperation agreement with Elliott Investment - The Goodyear Tire & Rubber Company announced enhancements to its Board of Directors in connection with a cooperation agreement with Elliott Investment Management L.P. Three highly experienced business leaders, mutually agreed-upon between Goodyear and Elliott, will join the Board effective immediately: Joseph R. Hinrichs, President & CEO, CSX Corporation; Max H. Mitchell, President & CEO, Crane Company; Roger J. Wood, Former Co-CEO, Tenneco. With these appointments, the Goodyear Board is composed of 15 directors, 13 of whom are independent. Goodyear will nominate up to 12 directors to stand for election at its 2024 annual meeting, including the three new directors. Further, as part of its agreement with Elliott, the Board is establishing a Strategic and Operational Review Committee to oversee and support the Board and management's review of various strategic and operational alternatives to maximize sustainable shareholder-value creation and build upon a number of initiatives that Goodyear has been executing. The committee will be chaired by Goodyear Chairman, CEO and President Richard J. Kramer, and will include James A. Firestone, Thomas L. Williams, Max H. Mitchell and Roger J. Wood. The committee reviews will be supported by Goodyear's financial advisors and a leading consulting firm. The cooperation agreement that Goodyear has entered into with Elliott contains customary standstill, voting, non-disparagement and other provisions.

09:13 EDT Jupiter Wellness announces launch of Cosmofix MinoxiBoost in India - Jupiter Wellness announced the launch of Cosmofix MinoxiBoost in India in collaboration with its regional distributors, Sanpellegrino Cosmetics Pvt Ltd and Cosmofix Technovation Pvt Ltd, which have the exclusive distribution rights to Jupiter Wellness' patented hair growth technology in 31 countries in Asia and the Middle East including India, the Philippines, Malaysia, Kuwait, Morocco, and Saudi Arabia. In addition to upfront payments received upon signing of the distribution agreement in June of 2022, Jupiter is entitled to receive royalties on all sales of MinoxiBoost and soon-to-launch MinoxiClean in India and the 30 other countries included in the distribution agreement. The collaboration between Jupiter Wellness, Sanpellegrino and Cosmofix Technovation showcases a commitment to bringing innovative products to the Indian market.

09:10 EDT OncoCyte announces publication of data on VitaGraft Kidney - Oncocyte Corporation announced the publication of new data demonstrating VitaGraft Kidney's novel ability to help physicians treat kidney transplant patients more precisely, quickly, and effectively. The test was able to distinguish between two prevalent causes of premature graft failure: biopsy-proven antibody-mediated rejection and recurrent IgA nephropathy. This is the first publication investigating this application of VitaGraft's donor-derived cell-free DNA diagnostic technology for kidney transplant patients. The data was published as a paper in the peer-reviewed journal Kidney International Reports. This ongoing prospective, observational trial evaluated VitaGraft Kidney's dd-cfDNA diagnostic technology as a tool to discriminate between recurrent IgAN and ABMR. In the study, VitaGraft Kidney demonstrated higher sensitivity and specificity for detection of ABMR over routine tests. Differentiating between recurring IgAN and ABMR could help physicians select the appropriate treatment for the patient more quickly, while potentially also avoiding unnecessary procedures and treatments. In the paper, the authors highlight the limited value of currently marketed tests for the identification of treatable early-stage ABMR and suggest that dd-cfDNA testing could be a useful longitudinal management tool.

09:08 EDT Micron announces expansion to Crucial portable SSD portfolio - Micron Technology announced the Crucial X9 Pro Portable SSD and Crucial X10 Pro Portable SSD, two new performance offerings in the Crucial Pro Series product portfolio, designed for content creators such as photographers, videographers, designers, or any performance-seeking consumer. Both drives utilize Micron TLC NAND and leverage a revolutionary single-ASIC portable storage architecture to enable a breakthrough, ultra-compact, lightweight form factor and allows Micron to ship the most capacity per square millimeter in the industry. With either the Crucial X9 Pro and X10 Pro, users can safely store, transport and backup important videos, photos, files and more on the go, without cloud or internet access at lightning-fast speeds.

09:05 EDT Inpixon enters merger agreement with XTI Aircraft Company - Inpixon announced it has entered into a definitive merger agreement with XTI Aircraft Company, an aviation company developing the TriFan 600, a fixed-wing, vertical takeoff and landing aircraft. The enterprise value of XTI was ascertained by an independent financial advisory firm to be within the range of $252M-$343M. XTI's valuation was determined after comparison with certain public companies with similar business models to XTI in the air travel/VTOL segment of the aviation industry, with an average enterprise value of approximately $1.6B. If completed, the merger will result in a combined publicly traded company that will focus on advancing the TriFan 600 to market, as well as continuing to offer Inpixon's real-time location systems technology to manufacturing and warehousing facilities for streamlined operations, greater efficiency, and improved safety. The companies will launch a merger information portal at xti-inpx-merger.com where interested parties can keep abreast of transaction news. The merger agreement provides for XTI shareholders to own approximately 60% of the outstanding shares of common stock of the post combination company, and Inpixon shareholders to retain approximately 40% of the outstanding shares of common stock of the post combination company as of closing. However, that ratio is subject to adjustment and determination of the final exchange ratio in accordance with the terms of the merger agreement. Upon closing of the transaction, the combined company is planning to operate under the name XTI Aerospace and to trade on the Nasdaq Capital market under the symbol XTIA or other symbol to be announced. Inpixon's industrial RTLS solutions will be offered as a separate business line of XTI Aerospace, and XTI Aircraft Company will operate as a wholly owned subsidiary of XTI Aerospace. In connection with the closing of the transaction, Nadir Ali and Wendy Loundermon are expected to resign as chief executive officer and chief financial officer of Inpixon. It is anticipated that XTI's current board member and chief financial officer, Scott Pomeroy, will become the chairman and chief executive officer of XTI Aerospace, with XTI founder David Brody becoming a member of the board of directors of XTI Aerospace. Michael Hinderberger will continue in his current role as chief executive officer of XTI Aircraft Company, leading the technical development of the TriFan 600. Soumya Das, the chief operating officer of Inpixon, will continue to lead the RTLS business line. The transaction has been unanimously approved by the Boards of Directors of Inpixon and XTI, and by XTI's controlling shareholders, and is subject to approval by Inpixon shareholders, as well as the satisfaction of customary closing conditions. The proposed merger is expected to be completed by the fourth quarter of 2023.

09:03 EDT Oak Ridge Financial announces promotions within leadership - Oak Ridge Financial Services, the parent company of Bank of Oak Ridge, officially announces the promotion of Jeffrey Finberg, Marissa Parrish, and S. Brady Young to Executive Vice President, EVP. The Company also announces the promotion of Finberg to Chief Credit Officer. These promotions went into effect in March of 2023. Jeffrey Finberg joined Bank of Oak Ridge in April 2006 and has since held successive roles of increasing responsibility and scope. Marissa Parrish joined Bank of Oak Ridge in July 2011 and currently serves as Chief People & Marketing Officer. Parrish has more than 20 years of experience in human resources, marketing, and management. S. Brady Young joined Bank of Oak Ridge in July 2010 and currently serves as Chief Retail Banking Officer.

09:02 EDT Amazon.com, iRobot amend merger price to $51.75 per share - Amazon (AMZN) and iRobot (IRBT) announced that they have agreed to amend the existing terms of their merger agreement to reflect a change to the price per share. Under the amended terms, Amazon will pay $51.75 per share revised from $61.00 per share. At the same time, iRobot has entered into a $200M financing facility to fund its ongoing operations. For Amazon, the change in price per share is expected to be largely offset by the planned increase in iRobot's net debt under the new financing facility. "We've reached an amended agreement with Amazon that reflects the incurrence of iRobot's new debt," said Colin Angle, chairman and CEO of iRobot. "iRobot is taking on new financing that we believe is sufficient to support our operations in a hyper competitive environment and meet our liquidity needs as well as pay off iRobot's existing debt. This new financing is the outcome of a thorough process and represents the best terms reasonably obtainable on additional financing to support our operations." "We are pleased to support iRobot in this way so they can continue inventing and delivering for customers while our proposed acquisition awaits regulatory approval," said Dave Limp, SVP of Amazon Devices. "As we said when we announced the merger last August, customers love iRobot products and we're excited to work with them to invent in ways that make customers' lives easier and more enjoyable." Completion of the transaction remains subject to customary closing conditions, including regulatory approvals and approval of the amended merger agreement by iRobot's stockholders. Amazon and iRobot are working cooperatively with the relevant regulators in their review of the merger.

09:02 EDT Blue Water Biotech teams with UpScriptHealth to launch telemedicine platform - Blue Water Biotech announced an agreement with UpScriptHealth to generate a robust, online telemedicine platform to distribute Blue Water's benign prostatic hyperplasia asset, ENTADFI. Under this agreement, UpScript will build an online platform to support BPH patients throughout the prescription and coverage process, as well as provide eligible patients access to ENTADFI mailed directly to their homes. "Telehealth, with its increasing popularity in recent years, is a great opportunity to improve not only patient access to therapy, but improve patient lives throughout the entire treatment journey," said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water. "Together with UpScript and through this platform, intend to provide eligible BPH patients direct access to ENTADFI(R) online, minimizing the need for specialist visits and trips to the pharmacy that can be burdensome to patients. With UpScript's proven track record and unwavering dedication to easing patient challenges through telehealth solutions, we are thrilled to take this next step with UpScript and look forward to launching this campaign."This agreement with UpScript represents a milestone reached by Blue Water in its efforts to launch its commercial portfolio, highlighted by ENTADFI, that was previously announced in a letter to shareholders from Mr. Hernandez earlier this month.

08:59 EDT Verizon says taking lead matter 'very seriously' - Says consulting internal and external experts. Says still reviewing records, "more work to do."

08:55 EDT Inpixon trading halted, news pending

08:52 EDT Verizon says 'records incomplete' on lead sheath cable in network - Says "far too soon" to make any financial projections on cost of removing lead sheath cable in network. Says any estimates "not useful."

08:48 EDT Barra: GM has 'long history' of negotiating contracts with both unions

08:45 EDT Teradata acquires Stemma Technologies, terms undisclosed - Teradata announced that it has acquired Stemma Technologies, a cloud-native, fully managed, data catalog solution. Founded in 2020, Stemma is recognized for its innovation and adept use of AI and machine learning that helps users discover, trust, and use their data and metadata more effectively. The terms of the transaction were not disclosed.

08:45 EDT Marriott Vacations CFO Anthony Terry to retire, Jason Marino to succeed - Marriott Vacations announced Jason Marino has been named executive VP and CFO effective September 30. He will succeed Anthony Terry, who announced his intent to retire from the company earlier this year. Marino currently serves as senior VP, strategy, financial planning & analysis and operational finance - vacation ownership, leading a global team responsible for enterprise-wide finance and business functions, including strategic planning, M&A, budgeting and forecasting, capital structure allocation and financing activities.

08:42 EDT Verizon seeing operational improvements across the business - Says will continue to invest in pre-paid. Says customer payments "remain healthy." Says strengthening operational blueprint. Says lead infrastructure represents a "small percentage" of the network. Comments taken from Q2 earnings conference call.

08:41 EDT General Motors planning new generation of Bolt EV, says CEO

08:39 EDT GM: Ultium battery production delayed by issues at equipment supplier

08:39 EDT 3D Systems announces materials to expand capabilities of SLA, Figure 4 platforms - 3D Systems announced new materials to enhance its Stereolithography and Figure 4 portfolios - Accura AMX Tough FR V0 Black, Figure 4 Tough FR V0 Black, and Figure 4 JCAST-GRN 20. These new high-performance materials are enabling efficient production of end-use parts in industries such as automotive, aerospace, semiconductor, and consumer goods.

08:37 EDT Bridgeline Digital announces Spectrum Control has chosen HawkSearch - Bridgeline Digital announced that Spectrum Control has chosen HawkSearch, Bridgeline's advanced AI-based search solution, to power its ecommerce platform. Spectrum Control has entered into a multi-year agreement and plans to drive conversions on its eCommerce platform with powerful HawkSearch features such as Smart Search and Recommendations. The microwave signal solutions leader will leverage HawkSearch's Rapid UI framework with past industry experience for a smooth, fast implementation.

08:36 EDT BYND Cannasoft provides EZ-G device milestones for 2H23 - BYND Cannasoft announced several milestones for the second half of 2023 on the development of its groundbreaking EZ-G Device. The EZ-G device, a therapeutic solution utilizing AI and machine learning, could enhance therapeutic approaches for women's health issues by offering cutting-edge technology to cater to the evolving needs of consumers. Moreover, the company is actively negotiating with synergistic businesses, particularly those in the CBD oils sector, for a transformative transaction. BYND Cannasoft is pleased to provide the following key milestones in the development of the EZ-G Device: Finishing the Prototype of the EZ-G Device in 60 Days: BYND Cannasoft plans to reiterate its commitment to innovation by accomplishing the development of the EZ-G Device's initial prototype within a 60-day timeline. The Company's team of experts intends to create a prototype that showcases the technology's potential to disrupt the market. EZ-G Device Focus Group Experience within 60 Days: In line with BYND Cannasoft's customer-centric approach, the Company plans to engage a focus group to perform rigorous testing and evaluation of the EZ-G Device over the next 60 days. This process will provide valuable insights and user feedback, helping to refine the product to exceed customer expectations. Finalizing the EZ-G Device Prototype and Software by the End of the Fourth Quarter: Building upon insights gained from the focus group, BYND Cannasoft intends to build on its recent successful completion of the laboratory testing phase by fine-tuning the EZ-G Device's prototype and software. The Company is dedicated to refining user experience and functionality to introduce a superior product. Going to Market with the EZ-G Device in the First Quarter of 2024: With a meticulously developed and thoroughly tested product, BYND Cannasoft's management believes the Company is on track for a market launch of the EZ-G Device in the first quarter of 2024. The Company anticipates that the product will set new industry benchmarks.

08:35 EDT Sensus Healthcare completes installation of first SRT system in Ireland - Sensus Healthcare has installed the first SRT-100 System in Ireland at Dublin's Beacon Hospital. The system will provide a highly efficacious and non-invasive solution to treat the growing numbers of non-melanoma skin cancer patients in Ireland, which is estimated by the Irish Cancer Society to number 12,000 annually and growing. Commenting on the sale, Joe Sardano, chairman and chief executive officer of Sensus Healthcare, said, "We are thrilled to generate our first sale of an SRT System in Ireland and to a leading, technologically savvy facility such as Beacon Hospital. Beacon will serve as an example to the Irish dermato-oncology community of innovation in patient care. We expect that this system will be the first of many placed not only in Ireland, but in the United Kingdom as well."

08:34 EDT Esquire Financial reports Q2 EPS $1.10 vs. $1.47 last year - Reports Q2 book value per share $21.84 vs. $18.01 last year. "In order to support our continued expansion, growth, and strong performance metrics, we have recently hired six senior regional BDOs with deep industry connections and decades of experience in servicing the litigation market," stated Tony Coelho, Chairman of the Board of Directors. "Coupling these seasoned BDOs with our competitive advantages in data, analytics and digital marketing should allow us to continue to increase our market share nationally." "During the current quarter, we prudently deployed excess liquidity in our commercial and multifamily loan portfolios," stated Andrew C. Sagliocca, Vice Chairman, CEO and President. "We continue to see strong growth opportunities for core commercial deposits and the QSF sweep platform from our current and expanding commercial relationship banking clients nationally. Finally, by gaining access to the best talent through our recent regional BDO hires, we will be able to support continued expansion and excellence in client service across our national verticals."

08:33 EDT AMMO appoints Jared Smith as new CEO - AMMO announced Jared Smith as the Company's new Chief Executive Officer effective July 24, 2023. Smith has spent 17 years working in the firearm and ammunition sector, where he most recently spent more than five years as the General Manager with Fiocchi of America, a global manufacturer of premium ammunition for competition, hunting, and defense applications. During his tenure at Fiocchi, he held multiple positions, including Director of Procurement and Supply Chain, and subsequently, Vice President of International Strategy and Development.

08:32 EDT Third Harmonic Bio announces next-generation oral KIT inhibitor candidate - Third Harmonic Bio announced its next-generation product candidate, THB335, a potent, highly selective oral small molecule KIT inhibitor with a meaningfully differentiated product profile as compared to the company's first-generation product candidate THB001. Third Harmonic plans to file a U.S. IND and initiate clinical development of THB335 for the treatment of mast cell-mediated inflammatory diseases during the first half of 2024. The company also disclosed topline results of the Phase 1b clinical trial of THB001 for the treatment of chronic inducible urticaria, which was discontinued in December 2023 due to observed liver transaminitis in two of five patients enrolled. The results demonstrated evidence of clinical benefit in four of the five patients, achieving partial or complete responses despite early termination of the trial. "Based on extensive studies of our first-generation product candidate, THB001, we selected THB335, a next-generation compound that incorporates structural modifications which we believe maintain the potency and selective KIT inhibitory activity of THB001, while improving its safety profile," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "In addition, we are very encouraged by the clinical efficacy results observed in the discontinued Phase 1b study of THB001, demonstrating clinical responses in four out of five patients enrolled in the lowest planned dose cohort of the study. The combined structural modification and efficacy data give us confidence that we have the potential in THB335 for the optimal therapeutic profile against KIT for the treatment of mast cell-mediated inflammatory disorders. We are currently executing on our plans to be back in the clinic during the first half of next year."

08:26 EDT SMX signs sales cooperation agreement with Data Vault Holdings - SMX announced that it has entered into a Sales Cooperation Agreement with Data Vault Holdings which acts in the area of Web 3.0 technologies, crypto anchors and data software as a service, pursuant to which each party on a non-exclusive basis will effect introductions of potential clients to the other. Pursuant to the agreement, any transaction between a party and an introduced client shall entitle the introducing party to a commission on income received in the transaction for 48 months. In addition to entering into the Sales Cooperation Agreement, the companies intend to collaborate to advance Data Vault's Web 3.0 strategies for data visualization, inventory tracking and laboratory automation, using SMX's digital blockchain platform enhanced with a physical marker.

08:24 EDT StepStone Private Markets transitions to daily admittance, daily valuation - StepStone Private Wealth announced that StepStone Private Markets, SPW's core private markets evergreen fund, began publishing a daily net asset value allowing investors to invest on a daily basis effective July 17. SPRIM, the firm's $1.3 billion, broad-based private markets solution that spans private equity, private debt and real assets, is now available to accredited investors via numerous wealth management platforms on a daily basis. SPRIM will continue to offer quarterly redemptions.

08:22 EDT Qorvo releases QSPICE circuit simulation software - Qorvo announced the release of QSPICE, a new generation of circuit simulation software that provides power and analog designers significantly higher levels of design productivity through improved simulation speed, functionality and reliability. In addition to advancing the state of the art in analog simulation technology, QSPICE allows designers to simulate complex digital circuits and algorithms. Its unique combination of modern schematic capture and fast mixed-mode simulation make it the ideal tool to solve the increasingly complex hardware and software challenges faced by today's system designers.

08:21 EDT Uniti Group announces long-haul fiber agreement with internet provider - Uniti Group announced that it has signed a long-term contract with a prominent global internet provider, offering long-haul dark fiber connectivity across two key U.S. routes that connects 12 cities across the Midwest and the Southeast, and encompasses over 7,000 fiber strand miles. The Midwest path spans from Indianapolis, IN to Chicago, IL, then east to Ashburn, VA, with drops in Toledo, OH, Cleveland, OH, and Pittsburgh, PA. This route also features a critical segment from Toledo, OH to Detroit, MI. The Southeast route establishes a seamless network corridor from New Orleans, LA to Mobile, AL, then up to Montgomery, AL. Each of these fiber routes bolsters the network infrastructure, improves diversity and enables advanced network capabilities for our customer.

08:19 EDT MoonLake completes randomization of patients for Phase 2 trial - MoonLake Immunotherapeutics announced that it has successfully completed randomization of the target 200 patients, several weeks ahead of schedule, in its global Phase 2 ARGO clinical trial evaluating Nanobody sonelokimab in active psoriatic arthritis. MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11th 2023. Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, said: "ARGO is MoonLake's second trial to have achieved faster completion of recruitment and randomization than expected. Reaching this stage well ahead of schedule for active psoriatic arthritis is an encouraging reflection of the interest in our clinical development programs. We are looking forward to all of the upcoming key MoonLake readouts and events and are excited about updating investors with our progress in due course."

08:18 EDT PDS Biotechnology to present immune response data from VERSATILE-002 trial - PDS Biotechnology announced that an abstract detailing immune response data from the VERSATILE-002 Phase 2 clinical trial investigating PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with unresectable, recurrent or metastatic human papillomavirus 16-positive head and neck cancer has been accepted for presentation at the European Society for Medical Oncology Congress 2023. The abstract, titled, "Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma," reports on the ability of PDS0101 in combination with KEYTRUDA to induce the right type of HPV16-specific multifunctional T cell responses in the treatment of advanced HPV16-positive head and neck cancer. PDS0101 is designed to stimulate a potent targeted T cell attack against HPV16-positive cancers. The immunological clinical data demonstrates the immunotherapy's potential to generate clinically-relevant multifunctional HPV16-targeted CD8 and CD4 T cells with minimal toxicity in advanced head and neck cancer patients.

08:17 EDT Oneok files proxy materials with SEC related to Magellan Midstream acquisition - ONEOK (OKE) announced that it has filed definitive proxy materials with the SEC in connection with ONEOK's pending acquisition of Magellan Midstream Partners (MMP). The ONEOK Special Meeting of Shareholders is scheduled to take place on Sept. 21. All shareholders of record of ONEOK common stock as of the close of business on July 24 will be entitled to vote their shares by proxy at the Special Meeting. The ONEOK board of directors unanimously recommends that shareholders vote "FOR" all proposals provided in detail in the definitive proxy statement. Proxy materials are expected to be mailed on or about July 28. As previously announced on May 14, 2023, ONEOK will acquire all outstanding units of Magellan in a cash-and-stock transaction consisting of $25.00 in cash and 0.667 shares of ONEOK common stock for each outstanding Magellan common unit. The transaction is expected to close in the Q3, subject to approval by both ONEOK shareholders and Magellan unitholders, and other customary closing conditions.

08:16 EDT Worksport announces $1.6M order for hard-folding covers - Worksport announced a substantial $1,600,000 purchase order for its advanced hard-folding tonneau covers. This significant order follows closely on the heels of the Company's recently reported $720,000 purchase orders for its innovative soft-folding tonneau covers. Production of the hard-folding covers is scheduled to kick off in a mere two weeks, adding to the Company's already soaring momentum.

08:15 EDT NV5 Global awarded $11M in contracts for electrical utility distribution - NV5 Global has been awarded $11 million in contracts to support the safety and reliability of electrical utility distribution. NV5 will provide engineering design, electrical engineering, surveying, and owner's engineer services for these projects to harden the electrical grid and improve electrical service reliability. In the Pacific Northwest, NV5 was selected for $9.4 million in utility hardening and grid connectivity projects. NV5 will provide owner's engineering and utility design services for the underground conversion of approximately 34 miles of power lines. NV5 will also deliver electrical, structural, and civil engineering services to support the interconnection of battery storage systems, utility substations, and solar power generation. A utility in California also selected NV5 for a $1.5 million geospatial corridor mapping project for a 48-mile utility corridor. NV5 will derive planimetric and topographic data from lidar and imagery to provide engineering grade data for engineers to re-route a major transmission line.

08:14 EDT Treasure Global announces collaboration with KPDN - Treasure Global announced that it has collaborated with the Ministry of Domestic Trade and Cost of Living, KPDN, for the launch of the 'Payung Rahmah' program. The collaboration will bolster ZCITY's brand recognition, as well as attract additional users to the ZCITY app, TGL's proprietary digital lifestyle platform. As part of this, ZCITY will offer a comprehensive package of living essential e-vouchers on the ZCITY app for items such as petrol, food and bills. Sam Teo, Chief Executive Officer of TGL, said, "TGL cares deeply about the communities we operate in, and we are proud to have the Malaysian Government's trust as a partner in this important initiative. Inflation and the increasing cost of living are significant challenges for many Malaysians, and the Payung Rahmah program aims to combat these issues by offering discounts on living necessities. We also anticipate this initiative will help grow ZCITY's userbase, helping drive transaction numbers and increased revenue. As a leader in the digital innovation space, TGL is pleased to play a role in supporting this great cause, while also growing our brand presence, and we look forward to collaborating with the Malaysian government for additional future projects."

08:13 EDT Provident Financial appoints Gigliotti as SVP, Controller, Brown as SVP, CCO - Provident Bank (PFS) announces the addition of two talented and experienced leaders to the organization. Diane Gigliotti has joined the bank as Senior Vice President, SVP, Controller. Prior to joining Provident, she was Chief Financial Officer & Managing Director with the BBVA (BBVA) New York Branch. The Bank also announced that Mary Brown has been appointed to the position of Senior Vice President, Chief Compliance Officer, CCO. Most recently she served as Managing Director and Chief Compliance Officer for HSBC (HSBC)

08:11 EDT Aquestive Therapeutics to present topline data from anaphylm studies - Aquestive Therapeutics announced that two posters recapping the positive topline data from pharmacokinetic and pharmacodynamic studies of Anaphylm epinephrine sublingual film will be presented at the Aspen Allergy Conference, which will be held from July 30 - August 3 in Aspen, CO. "Having just presented the data from our PK and PD studies in two encore presentations at the Global Food Allergy Prevention Summit earlier this month, we are thrilled to be given the opportunity to continue to share both presentations at the upcoming Aspen Allergy Conference," said Daniel Barber, Chief Executive Officer of Aquestive. "Anaphylm continues to be a primary focus of our development program as it has the potential to provide a highly differentiated product to patients. Anaphylm is the first oral film candidate in development for the emergency treatment of severe allergic reactions, including anaphylaxis."

08:10 EDT Catalyst Pharmaceuticals CEO McEnany announces intention to retire - Catalyst Pharmaceuticals announced that Patrick McEnany, Catalyst's Co-Founder, Chairman, and Chief Executive Officer, CEO, has informed the Board of Directors of his intention to retire from his position as CEO by the end of 2023. McEnany remains the Company's largest individual stockholder and will continue to serve as CEO until his replacement is in place. Thereafter following his retirement as CEO, McEnany will continue to serve as non-Executive Chairman of Catalyst's Board of Directors. Once a successor has been appointed, McEnany will assist in the transition from his position as CEO and will continue to serve as non-executive Chairman of the Board for Catalyst.

08:10 EDT GM expects to double company revenue to $275B-$315B by 2030 - Sees ~50% revenue CAGR in software and new businesses by 2030 while Cruise targets annual revenue of $50B by 2030. The core auto business is targeting revenue CAGR of 4%-6% through 2030. Expects margin expansion to 12%-14% by 2030 with new businesses margins in excess of 20%. Targeting 1M annual EV capacity in North America by 2025. On track to open 4 battery cell plants targeting 160GWh of capacity.

08:09 EDT Bowman awarded $1.4M contract from J. Ranck Electric for 200 MW solar array - Bowman Consulting announced that the firm has been awarded a $1.4 M engineering design services contract by J. Ranck Electric for a new 200 MW solar array located in the Mid-Western United States. This contract builds on $2.1M of awards that the Company received from JRE in late 2022. Bowman will provide special use permit planning and engineering design services including civil design, electrical engineering for array design, and structural engineering for balance of systems equipment foundations. Given the flat topography of the location, Bowman's working closely with the local drainage commission to ensure conformance with complex regulations governing grading and drainage design relating to stormwater management.

08:08 EDT Academy Sports to open first location in Fredericksburg - Academy Sports and Outdoors will open its first location in Fredericksburg, Va. in the fall of 2023. This is Academy's second location in Virginia and will be over 77,000 square feet. Academy plans to continue its expansion efforts with the goal of opening 13 - 15 stores this year, and a total of 120 to 140 new stores by the end of 2027. The new location will carry a wide array of sports and outdoors products for customers to choose from to kickstart their fun. With help from knowledgeable team members, customers can expect to find the best assortment of athletic and casual shoes, sports and outdoors equipment, and clothing from top, national brands such as Nike, adidas, The North Face, Under Armour, Columbia, YETI, Carhartt, Winchester, Shimano, Titleist, Traeger and more.

08:07 EDT Genpact announces collaboration with Microsoft - Genpact (G) announced a collaboration with Microsoft (MSFT) that allows Genpact's global talent to access Microsoft's Azure OpenAI Service to enable them to unlock new opportunities to implement generative AI capabilities for clients. Genpact has identified various opportunities to leverage large language models, or LLMs, to drive enterprise efficiencies in areas such as transition management, global service desk management, infrastructure management, and other areas. Generative AI has the ability to help companies improve employee productivity, and enhance operational efficiency and agility, allowing Genpact's business teams to develop use cases that solve the many day-to-day challenges enterprises face. Azure's cloud infrastructure coupled with the flexibility of the Azure OpenAI Service will help accelerate these solution developments.

08:05 EDT LoanDepot names Melanie Graper chief human resources officer - LoanDepot announced that Melanie Graper has been named chief human resources officer, or CHRO, effective July 31. Graper will oversee all aspects of the company's human capital function and drive forward organizational aspects of LoanDepot's Vision 2025 plan. Graper, who succeeds Kevin Tackaberry, will report to president and CEO Frank Martell and be based in the organization's Orange County, California headquarters, along with other executive leadership. Graper most recently served as chief human resources officer of CoreLogic Inc. from 2019 to February.

08:01 EDT Integral Ad Science announces new partnership with Criteo - Integral Ad Science (IAS) announced a new partnership with Criteo (CRTO) to enable a first-to-market product for measuring onsite quality metrics for retail media. Through this new integration, IAS will enable viewability and invalid traffic measurement for Criteo's network of retail media partners, ensuring that marketers are reaching real users and maximizing engagement across this critical channel.

07:52 EDT Critical Elements Lithium appoints Sebastien Perreault as senior director mines - Critical Elements Lithium announced the appointment of Mr. Sebastien Perreault to the position of Senior Director Mines, Storage facilities and Camp. He has contributed to the successful start-up of several mining projects along with the establishment of operational teams at several mining companies, including Barrick, High River Gold, Sherritt, SEMAFO Inc. and IAMGOLD Corporation.

07:46 EDT Draganfly granted Transport Canada SFOC for wildfire suppression operations - Draganfly has been granted the Transport Canada Special Flight Operations Certificate for Beyond Visual Line of Sight and operations above 400 feet as part of its ongoing commitment to support wildfire suppression. This authorization grants the ability to cover extensive regions and rapidly deploy drones, crucial in providing essential data and facilitating early identification. These drones' real-time information will help firefighters identify and manage hotspots while ensuring communities remain safe.

07:39 EDT General Electric's first half of the year was 'solid,' says CEO

07:38 EDT Sonder Holdings launches Powered by Sonder hotel collection - Sonder Holdings has launched its first hotel collection, Powered by Sonder. Powered by Sonder is a collection of uniquely designed boutique hotels, powered by Sonder's technology and operated by Sonder. These hotels are infused with local flair, and have their own distinctive design aesthetic. In common with Sonder's wider portfolio of hotels and multi-unit apartment properties, Powered by Sonder hotels are located in the center of key travel destinations and provide app-enabled modern service, thoughtful amenities, and consistent high quality. 23 Sonder hotels across 13 markets are part of the Powered by Sonder collection, with new properties expected to be added. Among them are Atala in Paris, Chambers in New York City, and Yelo Jean Medecin in Nice.

07:36 EDT Amesite announces integration capability with LMS platforms - Amesite announces the rollout of capability to integrate with Learning Management Systems. Rollouts will begin on August 14, 2023. Dates that the integrations will be made available are as follows, enabling integrations to launch prior to the Fall, 2023 academic semester: Canvas: August 14, 2023; Blackboard: August 21, 2023; Google Classroom: August 21, 2023.

07:34 EDT Bullfrog AI issued U.S. patent for novel prodrugs of mebendazole - BullFrog AI Holdings announced that the United States Patent and Trademark Office will, on August 1, 2023, issue U.S. Patent No. 11,712,435 protecting the Company's novel prodrugs derived from mebendazole and their use in treating cancers and other diseases. The patented compounds exhibit improved solubility and oral bioavailability relative to the parent drug, thereby addressing a key difficulty encountered in evaluating the potential use of mebendazole for oncology indications.U.S. Patent No. 11,712,435 represents the first issued patent resulting from intellectual property BullFrog AI licensed from Johns Hopkins University in October 2022. BullFrog AI's exclusive, worldwide, royalty-bearing license includes the rights to commercialize prodrugs of mebendazole that demonstrate improved solubility and bioavailability relative to the parent compound.

07:33 EDT Anywhere Real Estate sees Q3 transaction volume down 10% y/y - "Looking ahead to the third quarter of 2023, the company expects our third quarter 2023 transaction volume to be down around 10% versus prior year. Consistent with industry forecasts, we still expect quarterly transaction volume comparisons to 2022 to improve throughout 2023, but expect full year 2023 transaction volumes to decline about 15-20% year-over-year and likely towards the better part of that range. Driven by these projected volume declines, the company continues to expect full year 2023 Operating EBITDA to be below 2022. However, the company still expects Free Cash Flow from operations to be modestly positive. This excludes the impact of cash expenses from the debt exchange transactions and any other non-recurring items. Based on year-to-date agent commission trends, we now expect full year commissions splits to increase about 50 to 75 basis points above 2022. The company continues to expect to realize cost savings of approximately $200 million in 2023, inclusive of the cost savings realized year-to-date in 2023."

07:23 EDT Logitech up 7% in pre-market at $67.41 after Q1 earnings beat, guidance raise

07:17 EDT Lithium Ionic reports initial drill results from Salinas Lithium Project - Lithium Ionic reports initial results from a planned 20,000-metre drill program at the Salinas Lithium Project. Drilling commenced in May 2023, following the acquisition of Salinas in March Salinas is located approximately 100 kilometres north of its Itinga Lithium Project, within the lithium-rich Aracuai Pegmatite District in the northern region of Minas Gerais State, Brazil. The Company is currently drilling to test and delineate multiple outcropping spodumene-rich pegmatite bodies identified by surface sampling and drilling in 2022 by the vendor. The Salinas mineralized pegmatite veins extend directly east of Latin Resources' Colina lithium deposit, which is reported to contain 45.2Mt grading 1.34% Li2O. Salinas Drill Intercept Highlights: 1.38% Li2O over 16m intersected near surface from 40.4m represents the strongest intercept to date at Salinas from a grade X width perspective; 1.60% Li2O over 12m from 68.2m; 1.55% Li2O over 9m from 129m; 1.26% Li2O over 11m from 63m; 1.34% Li2O over 10m from 94m. Blake Hylands, CEO, commented, "The initial results from Salinas confirm continuity of lithium mineralization with good grades and widths between the wide spaced drill holes completed in 2022 by the previous owner. These results, along with the significant growth seen at the Colina deposit only 500 metres west of our drilling site, as well as numerous historical artisanal workings that span decades of activity to the east, provide a strong indication of the potential for Salinas to quickly develop into an important part of our growing portfolio of lithium deposits."

07:14 EDT Medicenna Therapeutics to present as NBTS Research Roundtable - Medicenna Therapeutics announced that Dr. Fahar Merchant, the Company's President and CEO, was invited to participate and present at the Research Roundtable organized by the National Brain Tumor Society, NBTS. The event, titled "Use of External Control Data in Brain Tumor Clinical Trials" took place on July 20, 2023, in Washington, D.C. "Medicenna has been recognized for its innovative work in the treatment of rGBM, a uniformly fatal form of brain cancer. Compelling results from the Company's MDNA55 Phase 2b trial were recently published in the journal Neuro-Oncology, and when compared to a well-matched external control, bizaxofusp more than doubled the median survival in end-stage rGBM patients", said Dr. Merchant. "It was a privilege to share our pioneering efforts of leveraging data from patient registries together with promising Phase 2b results that secured Medicenna a precedent-setting FDA nod for the first-ever Phase 3 trial in rGBM using an external control arm. We believe that working alongside NBTS, together with experts from leading U.S. hospitals and pharma companies who share our vision to harness the power of external control data, may enhance the efficiency of clinical research and enable faster access to novel therapies for GBM" added Dr. Merchant.

07:14 EDT Maricopa County upgrades to mdf Commerce's source-to-contract solution - mdf commerce announced that Maricopa County, Arizona, has signed a 5-year agreement for the usage of our source-to-contract solution. Maricopa County will upgrade its existing suite of mdf commerce solutions to our full source-to-contract technology, allowing the County to streamline and simplify its procurement processes while fully leveraging the data and analytics benefits. This represents an investment for a much more modern technology.

07:13 EDT CareDx acquires organ transplant supply chain firm MediGO, no terms - CareDx announced the acquisition of MediGO, "in a strategic move to expand its digital health portfolio to serve the organ procurement organization, OPO, market while also bolstering its pre-transplant offerings aimed at shortening transplant wait times and increasing access to donated organs. "MediGO shares our patient-centric mission to improve the transplant journey and brings a wealth of expertise to CareDx. By leveraging our combined strengths, we will drive operational efficiencies, accelerate innovation, and deliver even greater value to the transplant ecosystem by addressing the serious organ transplant shortage," said Reg Seeto, CEO and President of CareDx. "The MediGO acquisition is in line with our mission, long-term growth strategy, and we're excited to invest in this best-in-class offering that is well-proven and rapidly gaining adoption."

07:10 EDT FibroGen appoints Thane Wettig as interim CEO - FibroGen announced the appointment of Thane Wettig as the Company's interim Chief Executive Officer effective as of July 23, 2023. Wettig has served as FibroGen's Chief Commercial Officer and a key member of the senior leadership team since June 2020. Wettig succeeds Chief Executive Officer Enrique Conterno, who resigned due to personal reasons. To support Wettig, Conterno will serve as a Special Advisor to the CEO during a transition period.

07:08 EDT Verizon CEO 'confident' in achieving full-year financial targets - "In the second quarter, we showed progress in our key priorities of growing wireless service revenue, delivering healthy consolidated adjusted EBITDA, and increasing free cash flow," said Chairman and CEO Hans Vestberg. "We look forward to extending our network leadership in the second half of the year by continuing our rapid C-Band deployment as we are laser focused on providing value to our customers. The steps that we have taken to improve our operational performance are working, and we are confident that we will achieve our financial targets for the full year."

07:07 EDT Sundial Growers, Nova Cannabis extend date for closing of partnership - SNDL Inc. and Nova Cannabis announced that while all other provincial approvals have been received, the continued review by one provincial regulator has necessitated a further extension of the outside date for the closing of the previously-announced strategic partnership. SNDL and Nova anticipate that the Transaction will close on or before August 25, 2023, subject to receipt of regulatory approval and the amendment to certain terms of the Transaction that are mutually satisfactory to SNDL and Nova.

07:07 EDT Eli Lilly extends expiration of tender offer to acquire Dice Therapeutics - Eli Lilly (LLY) announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of Dice Therapeutics (DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The company said, "The tender offer, which was previously scheduled to expire one minute past 11:59 p.m., Eastern time, on July 28, 2023, has been extended until one minute past 11:59 p.m., Eastern time, on Aug. 8, 2023, unless the tender offer is further extended or earlier terminated. The proposed acquisition is expected to close in the third quarter of 2023, subject to customary closing conditions, including the receipt of required antitrust clearance and the tender of at least a majority of the outstanding Shares as of the expiration of the tender offer."

07:06 EDT Verizon reports Q2 broadband net additions of 418,000 - Total broadband net additions of 418,000, reflecting a strong demand for fixed wireless and Fios products. This result included 384,000 fixed wireless net additions, an increase from 256,000 fixed wireless net additions in second-quarter 2022. This is the third consecutive quarter that Verizon reported more than 400,000 broadband net additions. Verizon now has nearly 2.3 million subscribers on its fixed wireless service. 54,000 Fios Internet net additions, an increase from 36,000 Fios Internet net additions in second-quarter 2022.

07:04 EDT Kimberly-Clark reports Q2 adjusted gross margin 34%, up 380 bps y/y - Driven by favorable net revenue realization and productivity, offsetting inflation.

06:38 EDT KalVista names Nicole Sweeny as Chief Commercial Officer - KalVista Pharmaceuticals announced the appointment of Nicole Sweeny as Chief Commercial Officer. Sweeny has more than 20 years of commercial strategy and leadership experience and has launched several approved products for rare diseases, including HAE. Sweeny previously was US Franchise Head of the Hereditary Angioedema team at Takeda Pharmaceuticals where she was responsible for the US launch of the market-leading HAE prophylaxis

06:36 EDT Thales to acquire Imperva from Thomas Bravo for $3.6B - Thales has reached an agreement with Thoma Bravo, a major software investment firm, for the acquisition of 100% of Imperva, a leading US-based data and application cybersecurity company, for an enterprise value of $3.6B. With this acquisition, Thales is taking its cybersecurity business to the next level. Imperva will enable growth in data security and Thales' entry into the attractive application security market. Thales total cybersecurity business will generate more than EUR 2.4 billion revenues. The transaction price is based on a $3.6 billion enterprise value. Significant value creation for Thales shareholders: $110 million of run rate cost and revenue synergies; Financial profile of DIS segment enhanced; Significant medium-term adjusted EPS accretion; Transaction adjusted ROCE3 above WACC in Year 5 post-closing; Imperva's integration into Thales will significantly expand Thales' addressable market in an already fast-growing sector. The new financial targets set for Thales' Digital Identity and Security activity are: 2024-2027 organic sales growth: +6 to +7%, 2027 EBIT3 margin to reach 16.5%. The acquisition is in line with Thales' disciplined capital deployment framework, with no impact on the Group existing dividend policy or ongoing share buyback programme. Closing of the transaction is expected by the beginning of 2024, upon completion of customary anti-trust and regulatory approvals. The closing of the transaction is expected by the beginning of 2024, subject to the completion of customary anti-trust and regulatory approvals.

06:33 EDT PulteGroup reports Q2 net new orders of 7,947 homes with a value of $4.3B - In Q2: Closings Increased 5% to 7,518 Homes; Average Sales Price Up 3% to $540,000; Home Sale Gross Margin of 29.6%; Net New Orders Increased 24% to 7,947 Homes with a Value of $4.3 Billion; Unit Backlog of 13,558 Homes with a Value of $8.2 Billion; Company Repurchased $250 Million of Shares in the Quarter.

06:29 EDT Compass Pathways publishes results of psilocybin treatment in anorexia nervosa - COMPASS Pathways announced the publication of a paper in Nature Medicine that demonstrates the potential for COMP360 psilocybin treatment in anorexia nervosa. The investigator-initiated open-label study was conducted by Drs. Walter Kaye and Stephanie Knatz Peck at the University of California San Diego School of Medicine and is believed to be the first clinical research study to report the effects of psilocybin treatment in anorexia nervosa. The study investigated the safety, efficacy, and tolerability of a single 25mg dose of COMP360 psilocybin, with psychological support, in female patients with anorexia nervosa. The results showed: 40% of participants experienced clinically significant reductions in eating disorder psychopathology at the three-month follow-up. Participants demonstrated statistically significant reductions from baseline in shape concerns at the one-month follow-up, and weight concerns at the three-month follow-up. Changes in eating concern were approaching significance at three-month follow-up. Five participants demonstrated an increase in body mass index at three-month follow-up. Changes in BMI were not statistically significant. Overall, the psilocybin experience was regarded as meaningful by participants. Ninety percent endorsed feeling more positive about life endeavors; 80% endorsed the experience as one of the top five most meaningful of their life; and 70% reported experiencing a shift in personal identity and overall quality of life. COMP360 psilocybin treatment was well tolerated. All adverse events were mild and transient in nature. No serious adverse events were reported.

06:25 EDT Hyundai Motor, Seoul National University opens joint battery research center - Hyundai Motor Group announced the inauguration of its Joint Battery Research Center with Seoul National University. This collaborative effort between the Group and SNU aims to advance battery technologies and foster industry-academia cooperation to establish global leadership in the battery field. Hyundai Motor Group to invest over KRW 30 billion by 2030 to facilitate research at the Joint Battery Research Center. Hyundai Motor Group Executive Chair Euisun Chung highlighted, "Our mission to develop a diverse range of mobility solutions equipped with advanced batteries is driven by our strong commitment to a sustainable environment for future generations. Through pioneering joint research and development efforts, we hope to empower all researchers to lead the way in propelling the transition to electrification of the mobility industry."

06:21 EDT Danaher sees Q3 base business core revenue down low-single digits - The company said, "For the third quarter 2023, the Company anticipates that non-GAAP base business core revenue will be down low-single digits year-over-year. For full year 2023, the Company anticipates that non-GAAP base business core revenue growth will be up low-single digits year-over-year."

06:18 EDT Dow Inc. expects macro environment to remain challenging in second half - "Looking ahead, we will continue to execute our near-term cost savings actions and advance our longer-term strategic priorities as we manage through a macro environment that is expected to remain challenging in the second half of the year," said Fitterling. "The actions we outlined in January are on track to deliver $1 billion of cost savings this year and we continue to benefit from the solid financial position and focus on cash flow generation we have demonstrated since Spin. Additionally, our disciplined and balanced capital allocation priorities continue to support our Decarbonize and Grow, and Transform the Waste investments to deliver long-term value creation for our stakeholders."

06:16 EDT Shell to sell its participating interest in Indonesia's Masela Block - Shell Upstream Overseas Services Limited, a subsidiary of Shell plc, has agreed to sell its participating interest in Indonesia's Masela Production Sharing Contract to Indonesia's PT Pertamina Hulu Energi and PETRONAS Masela Sdn. Bhd. The sale concerns SUOS' participating interest of 35% in the Masela PSC, which includes the Abadi gas project. The base consideration for the sale is $325M in cash with an additional contingent amount of $325M to be paid when the final investment decision, or FID, is taken on the Abadi gas project. The transaction has an effective date of January 1, 2023 and is targeted to be completed in Q3 2023, subject to completion of conditions, which include among others, regulatory approval to be obtained from the Indonesia's Ministry of Energy and Mineral Resources. "The decision to sell our participation in the Masela PSC is in line with our focus on disciplined capital allocation," said Zoe Yujnovich, Shell's Integrated Gas and Upstream Director. "We wish to thank all stakeholders, especially the Government of Indonesia for their support throughout the sales process. Shell remains active in Indonesia and continues to contribute to the country's energy transition journey."

06:13 EDT Immuron enrolls first cohort of 30 participants into Travelan clinical trial - Immuron announced the first cohort of 30 participants have been enrolled into the clinical trial to evaluate the efficacy of Travelan to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli, or ETEC. The clinical study is being led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US. The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of Travelan compared to a placebo in a controlled human infection model, or CHIM. The primary efficacy outcome is prevention and/or reduction of moderate to severe diarrhea. ClinicalTrials.gov Identifier: NCT05933525. The first cohort of 30 participants is anticipated to complete dosing and the in-patient stage of the study by the first week of August. The final 30 participants are anticipated to be enrolled into the study and complete the in-patient stage of the study by the end of October 2023. Headline results from the clinical trial expected to be reported in 1H 2024. The U.S. Department of Defense Uniformed Services University is also running a randomized clinical trial with Travelan in up to 868 participants. The USU has reported that to date it has successfully enrolled 347 participants into the clinical study following the initiation of enrolment and approximately 260 have completed the study. USU has extended the enrolment period and now expects to complete clinical trial enrolment in Q2 2024.

06:07 EDT Spotify reports Q2 total MAUs 551M vs. 433M last year - "The business performed very well in Q2, led by exceptionally strong MAU and Subscriber results. MAU net additions of 36 million were 21 million above guidance-an all-time high for the company-while Subscriber net additions of 10 million were 3 million ahead of guidance and the highest Q2 in company history. Revenue was in-line with guidance. Reported Gross Margin and Operating Loss were both primarily impacted by charges related to our actions to streamline operations and reduce costs. Excluding these items, Adjusted Gross Margin of 25.5% was in-line and up 22 bps Y/Y (consistent with how we guided the quarter). Adjusted Operating Loss of (EUR112M) was better than guidance, aided by lower marketing spend. Free Cash Flow was EUR9M in the quarter. Overall, we are encouraged by the strength we saw in Q2 and our momentum heading into the back half of 2023."

05:19 EDT Spire Global awarded EUR 16M contract from ESA - The European Space Agency, or ESA, has awarded Spire Global a EUR 16M phased contract for the EURIALO project, which will develop the preliminary design and demonstrator for a global space-based independent aircraft surveillance system. The project framework is part of ESA's program of Advanced Research in Telecommunications Systems, or ARTES, in its Directorate of Connectivity and Secure Communications.